Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 33, Issue 5, 2015, Pages 433-442

  Ramalingam, Suresh S ^a   Shtivelband, Mikhail ^b   Soo, Ross A ^c   Barrios, Carlos H ^d   Makhson, Anatoly ^g   Segalla, José G M ^e   Pittman, Kenneth B ⁱ   Kolman, Petr ^j   Pereira, Jose R ^f   Srkalovic, Gordan ^k   Belani, Chandra P ^l   Axelrod, Rita ^m   Owonikoko, Taofeek K ^a   Qin, Qin ⁿ   Qian, Jiang ⁿ   McKeegan, Evelyn M ⁿ   Devanarayan, Viswanath ⁿ   McKee, Mark D ⁿ   Ricker, Justin L ⁿ   Carlson, Dawn M ⁿ   Gorbunova, Vera A ^h   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ironwood Cancer and Research Center   (United States)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e Hospital Amaral Carvalho   (Brazil)

^f IBCT Instituto Brasileiro de Cancerologia Torácica   (Brazil)

^g Moscow City Oncology Clinical Hospital 62   (Russian Federation)

^h N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

ⁱ QUEEN ELIZABETH HOSPITAL   (Australia)

^j Hospital Kyjov   (Czech Republic)

^k Department of Medical Oncology and Hematology   (United States)

^l PENN STATE CANCER INSTITUTE   (United States)

^m THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

ⁿ ABBVIE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; LINIFANIB; PACLITAXEL; PLACEBO; TUMOR MARKER; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N1-(2-FLUORO-5-METHYLPHENYL)UREA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SMOKING; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDAZOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PHENYLUREA COMPOUNDS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922341727     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.7173     Document Type: Article

References (27)

1. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
2. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
3. Herbst RS, Onn A, Sandler A: Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol 23:3243-3256, 2005
4. Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Engl J Med 359:1367-1380, 2008
5. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82: 1427-1432, 2000
6. Giaccone G: The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 13:1961-1970, 2007
7. Zhou J, Goh BC, Albert DH, et al: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside. J Hematol Oncol 2:33, 2009
8. Albert DH, Tapang P, Magoc TJ, et al: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5:995-1006, 2006
9. Albert DH, Reuter D, Tapang P, et al: Efficacy of linifanib in preclinical models of NSCLC with wild-type and mutated KRAS. 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011 (abstr M011.13)
10. Wong CI, Koh TS, Soo R, et al: Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27:4718-4726, 2009
11. Tan EH, Goss GD, Salgia R, et al: Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:1418-1425, 2011
12. Ramalingam SS, Owonikoko TK, Khuri FR, et al: Phase 2 study of linifanib (ABT-869) in combination with carboplatin/paclitaxel (CP) in patients with advanced or metastatic non-small cell lung cancer (NSCLC): Lead-in cohort results. 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011 (abstr 6638)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Mauer AM, Cohen EE, Ma PC, et al: A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 3:631-636, 2008
15. Rudin CM, Mauer A, Smakal M, et al: Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. J Clin Oncol 29:1075-1082, 2011
16. McKeegan EM, Ansell PJ, Davis G, et al: Baseline plasma biomarker signature is associated with improved survival in advanced NSCLC patients on linifanib. Ann Oncol 23:173, 2012 (suppl 9; abstr 505)
17. Pal SK, Figlin RA, Reckamp K: Targeted therapies for non-small cell lung cancer: An evolving landscape. Mol Cancer Ther 9:1931-1944, 2010
18. Scagliotti G, Novello S, von Pawel J, et al: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842, 2010
19. Paz-Ares LG, Biesma B, Heigener D, et al: Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 30:3084-3092, 2012
20. Goss GD, Arnold A, Shepherd FA, et al: Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55, 2010
21. Laurie SA, Solomon BJ, Seymour L, et al: A randomized double-blind trial of carboplatin plus paclitaxel (CP) with oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. J Clin Oncol 30, 2012 (suppl; abstr 7511)
22. Scagliotti GV, Vynnychenko I, Park K, et al: International, randomized, placebo-controlled, doubleblind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30:2829-2836, 2012
23. Arrieta O, Saavedra-Perez D, Kuri R, et al: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: A prospective analysis. BMC Cancer 9:119, 2009
24. Kulpa J, Wójcik E, Reinfuss M, et al: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48:1931-1937, 2002
25. Tomita M, Shimizu T, Ayabe T, et al: Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 30:3099-3102, 2010
26. Ramalingam SS, Shtivelband M, Soo RA, et al: Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLC. J Clin Oncol 30, 2012 (suppl; abstr 7512)
27. Brahmer JR, Dahlberg SE, Gray RJ, et al: Sex differences in outcome with bevacizumab therapy: Analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol 6:103-108, 2011